Advertisement

Topics

Schering Corporation Company Profile

22:21 EDT 19th September 2017 | BioPortfolio

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


News Articles [75 Associated News Articles listed on BioPortfolio]

Former Schering-Plough CEO Says This is the 'Worst Solution' to the Drug Pricing Dilemma

  Life Sciences Jobs   ...

Intrinsic4D Inc. Announces Public Sale of Substantially all of the Assets of its Operating Subsidiary and Transfer to NEX

TORONTO, ONTARIO -- (Marketwired) -- 05/11/17 -- Intrinsic4D Inc. (the "Corporation") (TSX VENTURE: IFD) provides stakeholders with an update in relation to its financial status and solvency. Publi...

Savaria Announces Resignation of Director and Appointment of New Director

LAVAL, QUEBEC -- (Marketwired) -- 07/07/17 -- Savaria Corporation (TSX: SIS) ("Savaria" or the "Corporation"), one of North America's leaders in the accessibility industry, is pleased to announce th...

Ventripoint Announces Results of Annual Shareholders' Meeting and Grant of Options and DSUs

TORONTO, ONTARIO -- (Marketwired) -- 08/16/17 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSX VENTURE: VPT) announces that at its Annual General Meeting on August 14, 2017 ...

CombiMatrix Corporation Reports First Quarter 2017 Financial and Operating Results

Achieves record reproductive health revenues on higher test volumes and average revenue per test, expands gross margin, significantly narrows operating loss and reports record cash collections Af...

NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation

REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) diso...

Geron Corporation Reports First Quarter 2017 Financial Results and Recent Events

MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2017 and recent events. First Quarter...

ADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation

RAMSEY, N.J., May 30, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) announced today that its stockholders voted to approve ADMA’s previously announced acquisition of certain asset...

PubMed Articles [0 Results]

None

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis

The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (lor...

Remicade Infusion Management Program (Study P04466)

Schering Canada plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infu...

Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions

To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating tablets of Ohm Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc., USA) with Claritin® Re...

Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions

The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-...

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions

The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under non-fasting conditions.

Companies [207 Associated Companies listed on BioPortfolio]

Schering Health Care Limited

Schering Health Care is the UK subsidiary of Schering AG, an international pharmaceutical company with headquarters located in Berlin, Germany.Schering is a global company, with over 150 subsidiaries ...

Schering-Plough Corp.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies th...

Intervet/Schering-Plough Animal Health

Intervet/Schering-Plough Animal Health, based in Boxmeer, the Netherlands, is focused on the research, development, manufacturing and marketing of animal health products. The company offers customers ...

Schering Group

Responsible, sustainable business practices are a clear objective for Schering. While this means integrating ecological aspects, it also means fulfilling the growing expectations of many people with r...

Schering-Plough

Schering-Plough is committed to earning the trust of doctors, patients and customers every day. Our colleagues worldwide believe that trust is not easily granted, and that is the reason we focus each ...

More Information about "Schering Corporation" on BioPortfolio

We have published hundreds of Schering Corporation news stories on BioPortfolio along with dozens of Schering Corporation Clinical Trials and PubMed Articles about Schering Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Schering Corporation Companies in our database. You can also find out about relevant Schering Corporation Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record